Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VTP-300,Nivolumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Barinthus Reports Phase 2b Hepatitis B Trial Achieves Cure, HBsAb Seroconversion
Details : Barinthus lead product VTP-300 (ChAdOx1-HBV) vaccine is being evaluated in mid-stage clinical trial studies in combination with Nivolumab for treating adults with chronic hepatitis B.
Product Name : VTP-300
Product Type : Vaccine
Upfront Cash : Inapplicable
November 15, 2024
Lead Product(s) : VTP-300,Nivolumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VTP-1000
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Barinthus Initiates Phase 1 Trial of VTP-1000 for Celiac Disease
Details : VTP-1000 is an investigational, injectable antigen-specific tolerance immunotherapy that utilizes Barinthus Bio’s platform. Currently, it is being evaluated for the treatment of celiac disease.
Product Name : VTP-1000
Product Type : Vaccine
Upfront Cash : Inapplicable
September 24, 2024
Lead Product(s) : VTP-1000
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VTP-200
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Barinthus Bio Reports Topline Data from APOLLO Trial Of VTP-200
Details : VTP-200 is an investigational immunotherapeutic regimen combining the ChAdOx vector and MVA vector encoding HPV antigens, evaluated for high-risk HPV infections in women.
Product Name : VTP-200
Product Type : Vaccine
Upfront Cash : Inapplicable
April 18, 2024
Lead Product(s) : VTP-200
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VTP-300,Nivolumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Barinthus Bio Completes Enrollment in HBV And Prostate Cancer Trials
Details : Barinthus lead product VTP-300 (ChAdOx1-HBV) vaccine is being evaluated in mid-stage clinical trial studies in combination with Nivolumab for treating adults with chronic hepatitis B.
Product Name : VTP-300
Product Type : Vaccine
Upfront Cash : Inapplicable
January 10, 2024
Lead Product(s) : VTP-300,Nivolumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VTP-500
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : CEPI
Deal Size : $34.8 million
Deal Type : Partnership
New Partnership Aims to Advance Vaccine Against MERS Coronavirus
Details : The partnership aims to fast-track the development of a vaccine candidate known as VTP-500 for the prevention of Middle East Respiratory Syndrome, the often fatal disease caused by the MERS coronavirus.
Product Name : VTP-500
Product Type : Vaccine
Upfront Cash : Undisclosed
December 21, 2023
Lead Product(s) : VTP-500
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : CEPI
Deal Size : $34.8 million
Deal Type : Partnership
Lead Product(s) : ChAdOx1-PCAQ,MVA-PCAQ
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VTP-850 (ChAdOx1-PCAQ) is a next-generation prostate cancer immunotherapeutic candidate which utilizes Vaccitech’s sequential dosing approach of two proprietary nonreplicating viral vectors, ChAdOx and MVA.
Product Name : VTP-850
Product Type : Vaccine
Upfront Cash : Inapplicable
December 06, 2023
Lead Product(s) : ChAdOx1-PCAQ,MVA-PCAQ
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VTP-300,ChAdOx1-HBV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
Details : VTP-300 (MVA-HBV) is a first antigen-specific immunotherapy consists of an initial dose using the ChAdOx platform and a secondary dose using MVA encoding multiple hepatitis B antigens, including full-length surface, modified polymerase and core antigens.
Product Name : VTP-300
Product Type : Vaccine
Upfront Cash : Inapplicable
March 28, 2023
Lead Product(s) : VTP-300,ChAdOx1-HBV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VTP-200
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VTP-200 is an investigational heterologous prime boost immunotherapy consisting of an initial dose using the ChAdOx vector and a second dose using MVA, both encoding the same HPV antigens, to elicit an immune response to HPV.
Product Name : VTP-200
Product Type : Vaccine
Upfront Cash : Inapplicable
March 20, 2023
Lead Product(s) : VTP-200
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VTP-300,ChAdOx1-HBV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VTP-300 administered as a monotherapy or in combination with a single administration of low-dose nivolumab at the time of the booster dose was administered with no treatment-related serious adverse events and infrequent transient transaminitis.
Product Name : VTP-300
Product Type : Vaccine
Upfront Cash : Inapplicable
July 11, 2022
Lead Product(s) : VTP-300,ChAdOx1-HBV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VTP-300,ChAdOx1-HBV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Meaningful, durable reductions of Hepatitis B surface antigen (HBsAg) were seen in some patients who received VTP-300 (MVA-HBV) as either a monotherapy or in combination with a single low dose of nivolumab at the booster dose.
Product Name : VTP-300
Product Type : Vaccine
Upfront Cash : Inapplicable
June 22, 2022
Lead Product(s) : VTP-300,ChAdOx1-HBV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable